|
【结 构 式】 
|
【分子编号】19064 【品名】(2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid 【CA登记号】 |
【 分 子 式 】C18H28N4O6S 【 分 子 量 】428.50968 【元素组成】C 50.45% H 6.59% N 13.07% O 22.4% S 7.48% |
合成路线1
该中间体在本合成路线中的序号：(XXI)The reaction of N-(tert-butoxycarbonyl [Boc])-4-O-methyl-L-tyrosine (I) with N,O-dimethylhydroxylamine (II) by means of dicyclohexylcarbodiimide (DCC) in THF gives the corresponding amide (III), which is reduced with LiAlH4 in ethyl ether yielding N-(tert-butoxycarbonyl)-4-O-methyl-L-tyrosinal (IV). The reductocondensation of (IV) with Nomega-tosyl-L-arginine (V) in methanol/acetic acid affords Nalpha-[2(S)-(tert-butoxycarbonylamino)-3-(4-methoxyphenyl)propyl]-Nomega-tosyl-L-arginine (VI), which is then attached to a polyestyrene resin (Merrifield resin) by means of DCC and dimethylaminopyridine (DMAP) to give the starting peptide-resin complex (IX). This resin (IX) is introduced into a Beckman 990 peptide synthesizer and submitted to successive amino acid coupling cycles (deprotection with TFA and coupling with (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate [BOP]) in order to introduce successively Boc-L-proline (X), Boc-L-serine (XII), Boc-L-(2-thienyl)alanine (XIV), Boc-glycine (XVI), Boc-L-(4-benzyloxy)proline (XVIII), Boc-L-proline (X), and Boc-L-(Nomega-tosyl)arginine (XXI) yielding resins (XI), (XIII), (XV), (XVII), (XIX), (XX), and the final resin (XXII), successively. The final peptide (RMP-7) is liberated from the resin (XXII) and simultaneously deprotected by a treatment with anhydrous HF with a 10% anisole and purified by HPLC over a C18 reverse phase column using trifluoroacetic acid/acetonitrile with a 0-25% gradient.
| 【1】 Graul, A.; Leeson, P.; Castañer, J.; RMP-7. Drugs Fut 1998, 23, 1, 32. |
| 【2】 Straub, J.A.; Musso, G.F.; Smart, J.L.; Lang, C.; Akiyama, A.; Bromination and subsequent catalytic tritiation of thienylalanine and 4-methyltyrosine residues in the bradykinin analog RMP-7. J Label Compd Radiopharm 1994, 34, 12, 1217-26. |
| 【3】 Malfroy-Camine, B.; Smart, J.L. (Alkermes, Inc.); Method for increasing blood-brain barrier permeability. WO 9116355 . |
| 【4】 Kozarich, J.W.; Musso, G.F.; Malfroy-Camine, B. (Alkermes, Inc.); Increasing blood-brain barrier permeability with permeabilizer peptides. WO 9218529 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XX) | 16890 | tert-butyl (2S)-2-[[(2S,4R)-2-[(6S,9S)-9-([(2S)-2-[(3S,6S)-5-benzyl-11-imino-3-(4-methoxybenzyl)-6-(methoxycarbonyl)-2,5,10,12-tetraazatridec-1-anoyl]pyrrolidinyl]carbonyl)-4,7-dioxo-12-phenyl-6-(2-thienylmethyl)-11-oxa-2,5,8-triazadodec-1-anoyl]-4-(benzyloxy)pyrrolidinyl]carbonyl]-1-pyrrolidinecarboxylate | C71H93N11O13S | 详情 | 详情 | |
| (XXI) | 19064 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (XXII) | 16892 | N(alpha)-[s(S)-[N(alpha)-tert-butoxycarbonyl-N(omega)-tosyl-arginyl-prolyl-[4(R)-benzyloxy]prolyl-glycyl-[3-(2-thienyl)]alanyl-)O-benzyl)seryl-propylamino]-1-(4-methoxyphenyl)propyl]-N(alpha)-benzyl-N(omega)-tosyl-arginine methyl ester | C84H111N15O16S2 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(XX)Compound (XVIII) was submitted to successive coupling cycles (deprotection with TFA, and coupling with DIPCDI) to introduce sequentially the following amino acids: (XVII) and (XX) yielding the following resins: (XIX) and (XXI), respectively.
| 【1】 Kyle, D.J.; Hiner, R.N. (Scios Inc.); Bradykinin antagonist peptides. JP 1995504155; US 5385889 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XVII) | 19061 | (2R)-1-(tert-butoxycarbonyl)-2-pyrrolidinecarboxylic acid; (2R)-1-(tert-butoxycarbonyl)tetrahydro-1H-pyrrole-2-carboxylic acid; N-alpha-t-BOC-D-proline | C10H17NO4 | 详情 | 详情 | |
| (XVIII) | 19060 | methyl (2S)-2-[([(2S,3aS,7aS)-1-[((2R,4S)-1-[(2S)-3-(benzyloxy)-2-[((2S)-2-[[2-([[(2S,4R)-4-(benzyloxy)pyrrolidinyl]carbonyl]amino)acetyl]amino]-3-phenylpropanoyl)amino]propanoyl]-4-propoxypyrrolidinyl)carbonyl]octahydro-1H-indol-2-yl]carbonyl)amino | C64H84N10O13S | 详情 | 详情 | |
| (XIX) | 19063 | methyl (2S)-2-[[((2S,3aS,7aS)-1-[[(2R,4S)-1-((2S)-3-(benzyloxy)-2-[[(2S)-2-([2-[([(2S,4R)-4-(benzyloxy)-1-[(2S)pyrrolidinylcarbonyl]pyrrolidinyl]carbonyl)amino]acetyl]amino)-3-phenylpropanoyl]amino]propanoyl)-4-propoxypyrrolidinyl]carbonyl]octahydro-1H-indol-2-yl)carbonyl]amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoate | C69H91N11O14S | 详情 | 详情 | |
| (XX) | 19064 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (XXI) | 19065 | methyl (2S)-2-([[(2S,3aS,7aS)-1-([(2R,4S)-1-[(2S)-2-[((2S)-2-[[2-([[(2S,4R)-1-[((2S)-1-[(2S)-2-amino-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoyl]pyrrolidinyl)carbonyl]-4-(benzyloxy)pyrrolidinyl]carbonyl]amino)acetyl]amino]-3-phe | C82H109N15O17S2 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(XXII)Compound (XVIII) was submitted to a coupling cycle (deprotection with TFA, and coupling with DIPCDI) to introduce the following amino acid (XXII) yielding the resin (XXIII). The final peptide was liberated from the resin (XXIII) and simultaneously deprotected by treatment with anhydrous HF containing a 10% anisole, and was purified by HPLC over a C18 reverse phase column, using as eluent acetonitrile-water containing a 0.1% of TFA.
| 【1】 Kyle, D.J.; Hiner, R.N. (Scios Inc.); Bradykinin antagonist peptides. JP 1995504155; US 5385889 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XXI) | 19065 | methyl (2S)-2-([[(2S,3aS,7aS)-1-([(2R,4S)-1-[(2S)-2-[((2S)-2-[[2-([[(2S,4R)-1-[((2S)-1-[(2S)-2-amino-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoyl]pyrrolidinyl)carbonyl]-4-(benzyloxy)pyrrolidinyl]carbonyl]amino)acetyl]amino]-3-phe | C82H109N15O17S2 | 详情 | 详情 | |
| (XXII) | 19064 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (XXIII) | 19067 | N-alpha-(tert-Butoxycarbonyl)-N-omega-tosyl-D-arginyl-(N-omega-tosyl)-L-arginyl-L-prolyl-(4(R)-benzyloxy)-L-prolyl-glycyl-L-phenylalanyl-(3-O-benzyl)-L-seryl-(4(R)-benzyloxy)-D-prolyl-(2S,3aS,7aS)-perhydroindol-2-ylcarbonyl-(N-omega-tosyl)-L-arginine methyl ester | C100H135N19O22S3 | 详情 | 详情 |
合成路线4
该中间体在本合成路线中的序号：(I)Nalpha-Boc-Ngamma-tosyl-L-arginine (I) was converted to the N,O-dimethyl hydroxamate (II) by treatment with dimethylhydroxylamine and BOP. Condensation of (II) with the Grignard reagent (IV), prepared from 6-bromo-1-hexene (III), produced ketone (V). Then, oxidative cleavage of the terminal alkene of (V) by means of NaIO4 and RuCl3 yielded carboxylic acid (VI).
| 【1】 DiMaio, J. (National Research Council of Canada); Thrombin inhibitors based on the amino acid sequence of hirudin. JP 1999502203; WO 9629347 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| 13361 | (Methoxyamino)methane; N,O-Dimethylhydroxylamine | 1117-97-1 | C2H7NO | 详情 | 详情 | |
| (I) | 19064 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (II) | 37329 | tert-butyl (1S)-4-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]-1-[[methoxy(methyl)amino]carbonyl]butylcarbamate | C20H33N5O6S | 详情 | 详情 | |
| (III) | 37330 | 6-bromo-1-hexene | 2695-47-8 | C6H11Br | 详情 | 详情 |
| (IV) | 37331 | bromo(5-hexenyl)magnesium | C6H11BrMg | 详情 | 详情 | |
| (V) | 37332 | tert-butyl (1S)-1-[3-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]propyl]-2-oxo-7-octenylcarbamate | C24H38N4O5S | 详情 | 详情 | |
| (VI) | 37333 | (7S)-7-[(tert-butoxycarbonyl)amino]-10-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]-6-oxodecanoic acid | C23H36N4O7S | 详情 | 详情 |
合成路线5
该中间体在本合成路线中的序号：(V)The peptide was synthesized by a solid-phase method using a p-methylbenzhydrylamine resin to which N1-Boc-N6-Fmoc-L-lysine (I) was coupled giving (II). To this solid phase the following protected amino acids Nalpha-Boc-N1-formyl-L-tryptophan (III), Nalpha-Boc-Nomega-Tos-L-arginine (V), Nalpha-Boc-D-(2-naphthyl)alanine (VII), Nalpha-Boc-Npi-L-histidine (IX) and Nalpha-Boc-Ogamma-Fm-L-aspartic acid (XI) were sequentially coupled yielding resins (IV), (VI), (VIII), (X) and (XII).
| 【1】 Al-Obeidi, F.A.; Sharma, S.D.; de L. Castrucci, A.; Kesterson, R.A.; Lu, D.; Hadley, M.E.; Cone, R.D.; Hruby, V.J.; Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem 1995, 38, 18, 3454. |
| 【2】 Hadley, M.E.; Hruby, V.J.; Sharma, S.D. (University of Arizona); Peptides having potent antagonist and agonist bioactivities at melanocortin receptors. US 5731408 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 25476 | (2S)-2-[(tert-butoxycarbonyl)amino]-6-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]hexanoic acid | 84624-27-1 | C26H32N2O6 | 详情 | 详情 |
| (II) | 25477 | 9H-fluoren-9-ylmethyl (5S)-6-amino-5-[(tert-butoxycarbonyl)amino]-6-oxohexylcarbamate | C26H33N3O5 | 详情 | 详情 | |
| (III) | 25478 | (2S)-2-[(tert-butoxycarbonyl)amino]-3-(1-formyl-1H-indol-3-yl)propionic acid | C17H20N2O5 | 详情 | 详情 | |
| (IV) | 25479 | 9H-fluoren-9-ylmethyl (5S)-6-amino-5-[[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1-formyl-1H-indol-3-yl)propanoyl]amino]-6-oxohexylcarbamate | C38H43N5O7 | 详情 | 详情 | |
| (V) | 19064 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (VI) | 25480 | tert-butyl (1S,4S,7S)-7-(aminocarbonyl)-15-(9H-fluoren-9-yl)-4-[(1-formyl-1H-indol-3-yl)methyl]-1-[3-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]propyl]-2,5,13-trioxo-14-oxa-3,6,12-triazapentadec-1-ylcarbamate | C51H61N9O10S | 详情 | 详情 | |
| (VII) | 23498 | (2R)-2-[(tert-butoxycarbonyl)amino]-3-(2-naphthyl)propionic acid | C18H21NO4 | 详情 | 详情 | |
| (VIII) | 25481 | tert-butyl (1R,4S,7S,10S)-10-(aminocarbonyl)-18-(9H-fluoren-9-yl)-7-[(1-formyl-1H-indol-3-yl)methyl]-4-[3-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]propyl]-1-(2-naphthylmethyl)-2,5,8,16-tetraoxo-17-oxa-3,6,9,15-tetraazaoctadec-1-ylcarbamate | C64H72N10O11S | 详情 | 详情 | |
| (IX) | 25482 | (2S)-3-[1-[(benzyloxy)methyl]-1H-imidazol-5-yl]-2-[(tert-butoxycarbonyl)amino]propionic acid | 83468-83-1 | C19H25N3O5 | 详情 | 详情 |
| (X) | 25483 | 9H-fluoren-9-ylmethyl (5S,8S,11S,14R,17S)-17-amino-5-(aminocarbonyl)-18-[1-[(benzyloxy)methyl]-1H-imidazol-5-yl]-8-[(1-formyl-1H-indol-3-yl)methyl]-11-[3-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]propyl]-14-(2-naphthylmethyl)-7,10,13,16-tetraoxo-6,9,12,15-tetraazaoctadec-1-ylcarbamate | C73H79N13O11S | 详情 | 详情 | |
| (XI) | 25484 | (2S)-2-[(tert-butoxycarbonyl)amino]-4-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-4-oxobutyric acid | C24H25NO8 | 详情 | 详情 | |
| (XII) | 25485 | N-(Tert-butoxycarbonyl)-[4-O-(9-fluorenylmethoxycarbonyl)]-L-aspartyl-[N-tau-(benzyloxymethyl)]-D-histidyl-D-2-naphthylalanyl-(N-omega-tosyl)-L-arginyl-(N-1-formyl)-D-tryptophyl-[N-6-(9-fluorenylmethoxycarbonyl)]-L-leucinamide; N-(Tert-butoxycarbonyl)-[4-O-(9-fluorenylmethoxycarbonyl)]-L-aspartyl-[N-tau-(benzyloxymethyl)]-D-histidyl-D-2-naphthylalanyl-(N-omega-tosyl)-L-arginyl-(N-1-formyl)-D-tryptophyl-[N-6-(9-fluorenylmethoxycarbonyl)]-L-leucinamide | C97H102N14O18S | 详情 | 详情 |
合成路线6
该中间体在本合成路线中的序号：(I)The title compound was synthesized by stepwise solid-phase peptide synthesis, starting from the protected arginine linked to PAM resin (I). After deprotection of the Boc group of (I) with trifluoroacetic acid, coupling with (Boc)-tryptophan (II) in the presence of TBTU and diisopropylethylamine afforded the dipeptide resin (III). Sequential deprotection and coupling cycles with (Boc)-D-cyclohexylalanine (IV), (Boc)-proline (VI), (Boc)-ornithine (VIII), and (Fmoc)-phenylalanine (X) provided the resins (V), (VII), (IX) and (XI), respectively.
| 【1】 Wong, A.K.; Shields, I.A.; Taylor, S.M.; Short, A.; Fairlie, D.P.; Haaima, G.; Finch, A.M.; Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol 1999, 126, 3, 551. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 19064 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (II) | 16114 | N-alpha-t-BOC-L-tryptophan; (2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propionic acid | 13139-14-5 | C16H20N2O4 | 详情 | 详情 |
| (III) | 29340 | (2S)-2-[[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C29H38N6O7S | 详情 | 详情 | |
| (IV) | 29348 | (2R)-2-[(tert-butoxycarbonyl)amino]-3-cyclohexylpropionic acid | C14H25NO4 | 详情 | 详情 | |
| (V) | 29341 | (6R,9S,12S)-6-(cyclohexylmethyl)-12-[3-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]propyl]-9-(1H-indol-3-ylmethyl)-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oic acid | C38H53N7O8S | 详情 | 详情 | |
| (VI) | 16734 | (2S)-1-(tert-butoxycarbonyl)tetrahydro-1H-pyrrole-2-carboxylic acid; N-alpha-t-BOC-L-proline; (2S)-1-(tert-butoxycarbonyl)-2-pyrrolidinecarboxylic acid | C10H17NO4 | 详情 | 详情 | |
| (VII) | 29342 | (2S)-2-[[(2S)-2-[[(2R)-2-([[(2S)-1-(tert-butoxycarbonyl)pyrrolidinyl]carbonyl]amino)-3-cyclohexylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C43H60N8O9S | 详情 | 详情 | |
| (VIII) | 29343 | (2S)-5-amino-2-[(tert-butoxycarbonyl)amino]pentanoic acid | 21887-64-9 | C10H20N2O4 | 详情 | 详情 |
| (IX) | 29344 | (2S)-2-[[(2S)-2-[((2R)-2-[[((2S)-1-[(2S)-5-amino-2-[(tert-butoxycarbonyl)amino]pentanoyl]pyrrolidinyl)carbonyl]amino]-3-cyclohexylpropanoyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C48H70N10O10S | 详情 | 详情 | |
| (X) | 19030 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-phenylpropionic acid; N-((9H-fluoren-9-ylmethoxy)carbonyl)-phenylalanine | 35661-40-6 | C24H21NO4 | 详情 | 详情 |
| (XI) | 29345 | Fluorenylmethoxycarbonyl-L-phenylalanyl-L-ornithyl-L-prolyl-D-cyclohexylalanyl-L-tryptophyl-L-(Nomega-tosyl)arginine | C67H81N11O11S | 详情 | 详情 |
合成路线7
该中间体在本合成路线中的序号：(I)The compound was prepared by solid-phase peptide synthesis on a PAM-resin. Starting from a N(alpha)-Boc-N(gamma)-Tos-L-arginine resin (I), cleavage of the Boc protecting group by means of trifluoroacetic acid provided Arg(Tos)-resin (II). Coupling of (II) with N(alpha)-Boc-L-tryptophan (III) using O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and diisopropylethylamine, followed by acid cleavage of the Boc group gave dipeptide resin (IV). This was in turn coupled and deprotected with the following amino acids N-Boc-D-cyclohexylalanine (V), N--Boc-L-proline (VII) and N(alpha)-Boc-N(delta)-Tos-L-ornithine (IX) to furnish the peptide resins (VI), (VIII), (X) and (XII), respectively.
| 【1】 Wong, A.K.; Finch, A.M.; Pierens, G.K.; Craik, D.J.; Taylor, S.M.; Fairlie, D.P.; Small molecular probes for G-protein-coupled C5a receptors: Conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J Med Chem 1998, 41, 18, 3417. |
| 【2】 Wong, A.K.; Fairlie, D.P.; Finch, A.M.; Wadi, S.K.; Craik, D.J.; Taylor, S.M.; Paczkowski, N.J.; Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 1999, 42, 11, 1965. |
| 【3】 Fairlie, D.; Wong, A.; Finch, A.M.; Taylor, S.M. (University of Queensland); Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors. EP 1017713; WO 9900406 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 19064 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (II) | 34498 | (2S)-2-amino-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C13H20N4O4S | 详情 | 详情 | |
| (III) | 16114 | N-alpha-t-BOC-L-tryptophan; (2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propionic acid | 13139-14-5 | C16H20N2O4 | 详情 | 详情 |
| (IV) | 34499 | (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C24H30N6O5S | 详情 | 详情 | |
| (V) | 29348 | (2R)-2-[(tert-butoxycarbonyl)amino]-3-cyclohexylpropionic acid | C14H25NO4 | 详情 | 详情 | |
| (VI) | 34500 | (2S)-2-[[(2S)-2-[[(2R)-2-amino-3-cyclohexylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C33H45N7O6S | 详情 | 详情 | |
| (VII) | 16734 | (2S)-1-(tert-butoxycarbonyl)tetrahydro-1H-pyrrole-2-carboxylic acid; N-alpha-t-BOC-L-proline; (2S)-1-(tert-butoxycarbonyl)-2-pyrrolidinecarboxylic acid | C10H17NO4 | 详情 | 详情 | |
| (VIII) | 34505 | (2S)-2-[[(2S)-2-[((2R)-3-cyclohexyl-2-[[(2S)pyrrolidinylcarbonyl]amino]propanoyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]pentanoic acid | C38H52N8O7S | 详情 | 详情 | |
| (IX) | 34501 | (2S)-2-[(tert-butoxycarbonyl)amino]-5-[[(4-methylphenyl)sulfonyl]amino]pentanoic acid | C17H26N2O6S | 详情 | 详情 | |
| (X) | 34502 | C50H68N10O10S2 | 详情 | 详情 |